<DOC>
	<DOCNO>NCT01743482</DOCNO>
	<brief_summary>This open label , single arm , single center , phase 2 study use antiangiogenic multikinase inhibitor pazopanib population patient germ cell tumor cure follow first subsequent chemotherapy line metastatic disease , follow eventual surgery .</brief_summary>
	<brief_title>Pazopanib Advanced Cisplatin-resistant Germ Cell Tumors</brief_title>
	<detailed_description />
	<mesh_term>Disease Progression</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<criteria>Male gender . Confirmation GCT histology base pathologic review Fondazione INT Milan . Unequivocal progression measurable disease . A minimum 2 maximum 3 platinumbased chemotherapy line metastatic disease . Firstline therapy consist least 3 cycle cisplatinbased chemotherapy . Prior single , tandem triple highdose chemotherapy course give frontline salvage therapy allow . Failure meet inclusion criterion . Concurrent treatment cytotoxic drug target therapy . Prior radiation therapy within 14 day trial start .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Testicular Cancer</keyword>
	<keyword>Germ Cell Tumors</keyword>
	<keyword>Salvage Therapy</keyword>
	<keyword>Pazopanib</keyword>
</DOC>